Pharmaceutical companies continue to pour billions into PD-1/VEGF bispecific antibodies after strong lung cancer results fueled industry enthusiasm. However, analysts increasingly question whether the sector is targeting the most valuable opportunity. As global Phase 3 programs expand, emerging evidence suggests
